miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.
Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, Liu W, Huang W, Hu J, Chen Z, Lao X, Chen C, Huang X, Lu Y, Ni X, Fang D, Wu D, Lu S, Jiang M, Qiu C, Wu Y, Qiu Q, Dong Y, Su Y, Zhao C, Zhong Z, Cai J, Liang Y.
Zou Z, et al. Among authors: cai j.
J Cell Mol Med. 2017 Sep;21(9):1929-1943. doi: 10.1111/jcmm.13114. Epub 2017 Apr 14.
J Cell Mol Med. 2017.
PMID: 28411377
Free PMC article.